Literature DB >> 22422702

Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users.

Ana Rath1, Annie Olry, Ferdinand Dhombres, Maja Miličić Brandt, Bruno Urbero, Segolene Ayme.   

Abstract

Rare disorders are scarcely represented in international classifications and therefore invisible in information systems. One of the major needs in health information systems and for research is to share and/or to integrate data coming from heterogeneous sources with diverse reference terminologies. ORPHANET (www.orpha.net) is a multilingual information portal on rare diseases and orphan drugs. Orphanet information system is supported by a relational database built around the concept of rare disorders. Representation of rare diseases in Orphanet encompasses levels of increasing complexity: lexical (multilingual terminology), nosological (multihierarchical classifications), relational (annotations-epidemiological data-and classes of objects-genes, manifestations, and orphan drugs-integrated in a relational database), and interoperational (semantic interoperability). Rare disorders are mapped to International Classification of Diseases (10th version), SNOMED CT, MeSH, MedDRA, and UMLS. Genes are cross-referenced with HGNC, UniProt, OMIM, and Genatlas. A suite of tools allow for extraction of massive datasets giving different views that can be used in bioinformatics to answer complex questions, intended to serve the needs of researchers and the pharmaceutical industry in developing medicinal products for rare diseases. An ontology is under development. The Orphanet nomenclature is at the crossroads of scientific data repositories and of clinical terminology standards, and is suitable to be used as a standard terminology.
© 2012 Wiley Periodicals, Inc.

Mesh:

Year:  2012        PMID: 22422702     DOI: 10.1002/humu.22078

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  135 in total

Review 1.  Human genotype-phenotype databases: aims, challenges and opportunities.

Authors:  Anthony J Brookes; Peter N Robinson
Journal:  Nat Rev Genet       Date:  2015-11-10       Impact factor: 53.242

2.  Coverage of rare disease names in standard terminologies and implications for patients, providers, and research.

Authors:  Kin Wah Fung; Rachel Richesson; Olivier Bodenreider
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

Review 3.  High-throughput mouse phenomics for characterizing mammalian gene function.

Authors:  Steve D M Brown; Chris C Holmes; Ann-Marie Mallon; Terrence F Meehan; Damian Smedley; Sara Wells
Journal:  Nat Rev Genet       Date:  2018-06       Impact factor: 53.242

4.  Phenolyzer: phenotype-based prioritization of candidate genes for human diseases.

Authors:  Hui Yang; Peter N Robinson; Kai Wang
Journal:  Nat Methods       Date:  2015-07-20       Impact factor: 28.547

Review 5.  Exploring the dark genome: implications for precision medicine.

Authors:  Tudor I Oprea
Journal:  Mamm Genome       Date:  2019-07-04       Impact factor: 2.957

6.  MendelVar: gene prioritisation at GWAS loci using phenotypic enrichment of mendelian disease genes.

Authors:  Sobczyk M K; Gaunt T R; Paternoster L
Journal:  Bioinformatics       Date:  2021-01-16       Impact factor: 6.937

Review 7.  Settling the score: variant prioritization and Mendelian disease.

Authors:  Karen Eilbeck; Aaron Quinlan; Mark Yandell
Journal:  Nat Rev Genet       Date:  2017-08-14       Impact factor: 53.242

8.  SCALEUS: Semantic Web Services Integration for Biomedical Applications.

Authors:  Pedro Sernadela; Lorena González-Castro; José Luís Oliveira
Journal:  J Med Syst       Date:  2017-02-18       Impact factor: 4.460

9.  [Computer-assisted diagnosis of rare diseases].

Authors:  T Müller; A Jerrentrup; J R Schäfer
Journal:  Internist (Berl)       Date:  2018-04       Impact factor: 0.743

10.  Hereditary metabolic diseases (HMDs) in adult practice in Ireland: a preliminary assessment.

Authors:  L Morrissey; C A Tiernan; D Lambert; E O'Reilly; E P Treacy
Journal:  Ir J Med Sci       Date:  2013-03-23       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.